Progression-free survival (PFS) and overall survival (OS) of patients with activated B-cell-like diffuse large B-cell lymphoma with or without A20 mutations.

<p>Progression-free survival (PFS) and overall survival (OS) of patients with activated B-cell-like diffuse large B-cell lymphoma with or without A20 mutations.</p

Prognostic Value of MET Gene Copy Number and Protein Expression in Patients with Surgically Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Published Literatures

<div><p>Background</p><p>The prognostic value of the copy number (GCN) and protein expression of the mesenchymal-epithelial transition (MET) gene for survival of patients with non-small cell lung cancer (NSCLC) remains controversial. This study aims to comprehensively and quantitatively asses the suitability of MET GCN and protein expression to predict patients' survival.</p><p>Methods</p><p>PubMed, Embase, Web of Science and Google Scholar were searched for articles comparing overall survival in patients with high MET GCN or protein expression with those with low level. Pooled hazard ratio (HR) and 95% confidence intervals (CIs) were calculated using the random and the fixed-effects models. Subgroup and sensitivity analyses were also performed.</p><p>Results</p><p>Eighteen eligible studies enrolling 5,516 patients were identified. Pooled analyses revealed that high MET GCN or protein expression was associated with poor overall survival (OS) (GCN: HR = 1.90, 95% CI 1.35–2.68, <i>p</i><0.001; protein expression: HR = 1.52, 95% CI 1.08–2.15, <i>p</i> = 0.017). In Asian populations (GCN: HR = 2.22, 95% CI 1.46–3.38, <i>p</i><0.001; protein expression: HR = 1.89, 95% CI 1.34–2.68, <i>p</i><0.001), but not in the non-Asian subset. For adenocarcinoma, high MET GCN or protein expression indicated decreased OS (GCN: HR = 1.49, 95% CI 1.05–2.10, <i>p</i> = 0.025; protein expression: HR = 1.69, 95% CI 1.31–2.19, <i>p</i><0.001). Results were similar for multivariate analysis (GCN: HR = 1.61, 95% CI 1.15–2.25, <i>p</i> = 0.005; protein expression: HR = 2.18, 95% CI 1.60–2.97, <i>p</i><0.001). The results of the sensitivity analysis were not materially altered and did not draw different conclusions.</p><p>Conclusions</p><p>Increased MET GCN or protein expression was significantly associated with poorer survival in patients with surgically resected NSCLC; this information could potentially further stratify patients in clinical treatment.</p></div

Main meta-analysis results.

<p>N: number of studies; HR: hazard ratio; RT-PCR, real-time polymerase chain reaction; FISH, fluorescent in situ hybridization; SISH, silver in situ hybridization; BISH, bright-field in situ hybridization; IHC, immunohistochemistry; NSCLC, non-small cell lung cancer; ADC, adenocarcinoma; SCC, squamous cell carcinoma; EGFR, epidermal growth factor receptor; WT, wild type.</p

Evaluation of human mesenchymal-epithelial transition (MET) by immunohistochemistry (IHC) in the selected studies in the selected studies.

<p>NA: not available; NSCLC, non-small cell lung cancer; ADC, adenocarcinoma; IHC, immunohistochemistry; HR: hazard ratio, obtained by estimated (E) or reported in text (R). “M” means the HR come from multivariate analysis, and “U” means HR come from univariate analysis; EGFR, epidermal growth factor receptor; HGF, hepatocyte growth factor.</p

Forest plot (A) assessing MET protein expression in NSCLC stratified by histological subtypes; Forest plot (B) assessing MET protein expression in NSCLC stratified by ethnic source.

<p>Forest plot (A) assessing MET protein expression in NSCLC stratified by histological subtypes; Forest plot (B) assessing MET protein expression in NSCLC stratified by ethnic source.</p

Evaluation of human mesenchymal-epithelial transition (MET) gene copy number in the selected studies.

<p>NA: not available; NSCLC, non-small cell lung cancer; ADC, adenocarcinoma; SCC, squamous cell carcinoma; RT-PCR, real-time polymerase chain reaction; FISH, fluorescent in situ hybridization; SISH, silver in situ hybridization; BISH, bright-field in situ hybridization; IHC, immunohistochemistry; Cappuzzo scoring system: MET FISH-positive group was defined mean MET gene copy number≥5 copies per cell; UCCC criteria: the University of Colorado Cancer Center) criteria, MET gene status was classified into two groups according to the frequency of tumor cells with specific copy numbers of the MET gene and the chromosome 7 centromere: FISH-positive MET MET to CEP7 ratio ≥2; >15 copies of the MET signals in >10% of tumor cells; small gene cluster [4–10 copies]; or innumerable tight gene clusters in >10% the tumor cells); EGFR, epidermal growth factor receptor; HR: hazard ratio, obtained by estimated (E) or reported in text (R). “M” means the HR come from multivariate analysis, and “U” means HR come from univariate analysis.</p

Meta-analysis of effects of the MET gene copy number on overall survival of patients with non-small cell lung cancer (NSCLC).

<p>Forest plot showing (A) the combined relative HR for OS by univariate analysis; (B) the combined relative HR for OS by multivariate analysis.</p

Forest plot (A) assessing MET gene copy number in NSCLC stratified by histological subtypes; Forest plot (B) assessing MET gene copy number in NSCLC stratified by ethnic source.

<p>Forest plot (A) assessing MET gene copy number in NSCLC stratified by histological subtypes; Forest plot (B) assessing MET gene copy number in NSCLC stratified by ethnic source.</p

Meta-analysis of effects of the MET protein expression on overall survival of patients with NSCLC.

<p>Forest plot showing (A) the combined relative HR for OS by univariate analysis; (B) the combined relative HR for OS by multivariate analysis.</p